



## OPEN

Reduced MCMV  $\Delta$ m157 viral clearance in the absence of TSAd

## SUBJECT AREAS:

VIRAL INFECTION  
INNATE IMMUNITYP. Moussa<sup>1\*</sup>, G. Abrahamsen<sup>2\*</sup>, N. Fodil<sup>1</sup>, R. P. Gopalakrishnan<sup>2</sup>, M. Mancini<sup>1</sup>, E. Dissen<sup>2</sup>, P. C. Sæther<sup>2</sup>, S. A. Wiltshire<sup>1</sup>, G. A. Boivin<sup>1</sup>, G. Caignard<sup>1</sup>, A. Spurkland<sup>2</sup> & S. M. Vidal<sup>1</sup>Received  
28 October 2014Accepted  
19 February 2015Published  
18 March 2015Correspondence and requests for materials should be addressed to A.S. ([anne.spurkland@medisin.uio.no](mailto:anne.spurkland@medisin.uio.no))

\* These authors contributed equally to this work.

<sup>1</sup>Department of Human Genetics and Department of Microbiology and Immunology, McGill University, Life Sciences Complex Montreal, QC, Canada, <sup>2</sup>Department of Anatomy, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

The T cell specific adapter protein (TSAd) is expressed in activated T cells and NK cells. While TSAd is beginning to emerge as a critical regulator of Lck and Itk activity in T cells, its role in NK cells has not yet been explored. Here we have examined susceptibility to virus infections in a murine model using various viral infection models. We report that TSAd-deficient mice display reduced clearance of murine cytomegalovirus (MCMV) that lack the viral MHC class I homologue m157, which is critical for Ly49H-mediated NK cell recognition of infected cells. In this infection model, NK cells contribute in the early stages of the disease, whereas CD8+ T cells are critical for viral clearance. We found that mice infected with MCMV  $\Delta$ m157 displayed reduced viral clearance in the spleen as well as reduced proliferation in spleen NK cells and CD8+ T cells in the absence of TSAd. Though no other immunophenotype was detected in the infection models tested, these data suggests that in the absence of the Ly49H ligand activation, NK cell and CD8+ T cell responses may be compromised in TSAd-deficient mice.


The recognition of antigens by the T cell receptor (TCR) is crucial in order to mediate T cell dependent responses. Triggering of the TCR leads to downstream signal propagation through a sequence of phosphorylation events modulated by various adaptor proteins. One of these adaptors, encoded by the *Sh2d2a* gene, is T cell specific adapter protein (TSAd), which is upregulated in activated T cells<sup>1</sup>.

T cells from *Sh2d2a*<sup>-/-</sup> mice display impaired production of IFN $\gamma$  upon TCR stimulation *in vitro*<sup>2</sup> and *in vivo*<sup>3</sup>. Early characterization of *Sh2d2a*<sup>-/-</sup> mice indicated that TSAd regulated autoimmunity, as T cells from *Sh2d2a*<sup>-/-</sup> mice were more resistant to antigen-induced cell death *in vivo* and older *Sh2d2a*<sup>-/-</sup> mice developed lupus-like symptoms<sup>3</sup>. Recently, improved T cell mediated protection against a transplanted myeloma in *Sh2d2a*<sup>-/-</sup> mice has been observed indicating that TSAd has a modulatory role in T cell mediated immune surveillance of cancer<sup>4</sup>. Though the characterisation of TSAd's function *in vivo* remains incomplete, these studies of TSAd suggest that the adaptor may be an important regulator of normal T cell function.

Biochemical characterization of TSAd's role in T cell activation has revealed that TSAd modulates the activity of Lck through multi-site docking of Lck to TSAd<sup>5</sup>. TSAd interacts with Itk, and primes Itk for phosphorylation by Lck<sup>6</sup>. It is thus likely that TSAd modulates signalling in activated T cells via interaction with Lck and Itk<sup>5-8</sup>.

Although TSAd is also highly expressed in NK cells<sup>9</sup>, the role of TSAd in NK cell function has not been explored. TSAd expression is induced upon activation of both T and NK cells and many of the known interaction partners for TSAd such as Lck, Itk, Src and MEKK2<sup>2,10-13</sup> are also expressed in NK cells. Importantly, Lck and Itk are expressed almost solely in T and NK cells and are important for efficient NK cell cytotoxicity and survival<sup>12-16</sup>.

There is compelling evidence for the role of NK cells against virus infections such as coxsackievirus B3<sup>17</sup>, influenza virus<sup>18</sup> as well as a potential role in herpes simplex virus 1 (HSV1) infection<sup>19</sup>. The best characterized model however remains the functional impact of NK cells against mouse cytomegalovirus (MCMV). In C57BL/6 mice, NK cells expressing the activating receptor Ly49H are responsible for the control of MCMV replication<sup>20,21</sup>. Ly49H binds to the viral glycoprotein m157 which is expressed at the surface of infected cells within hours of infection<sup>22</sup>. This binding triggers signaling pathways that activate NK cell effector functions such as IFN $\gamma$  secretion, release of cytotoxic granules containing perforin and granzymeB, as well as proliferation of Ly49H+ NK cell subsets<sup>22</sup>. The antiviral response to MCMV also involves CD4+ T cells, NK-T cells as well as neutrophils. CD4+ T cells are critical for controlling virus load in the salivary glands, but not the spleen, lung or liver<sup>23,24</sup>. A recent report demonstrated that depletion of neutrophils increases virus load in several organs including liver, salivary gland and lungs but not in the spleen<sup>25</sup>. NK-T cells are activated by MCMV and have been shown to synergize with NK cells for the clearance of MCMV in a BALB/c model, although this occurs principally in the liver<sup>26</sup>.



**Figure 1 | TSAd expression in NK cells.** (A) Human NK-L cell line was stimulated with 200 U/ml of IL-2 or 100 ng/ml of PMA and 500 ng/ml of Ionomycin (PMA/I) for the indicated time points. The cells were then lysed and the expression of TSAd was analysed by Western blot. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading control for total protein level (Top). Mouse NK cells prepared from total splenocytes and cultured with recombinant human IL-2 (1000 U/mL) for 6 to 8 days were stimulated with PMA/I for the indicated time-points and TSAd expression was monitored by Western blot as indicated above (Bottom). (B) Densitometry analysis was performed on the Western blot data, shown as TSAd/GAPDH ratio. (C and D) PBMC from healthy volunteers were stimulated with 200 U/ml of IL-2 or 200 µg/ml of PHA along with 200 U/ml of IL-2 or 100 ng/ml of PMA and 500 ng/ml of Ionomycin for 24 h. (C) TSAd expression in NK cells (CD3<sup>-</sup>, CD56<sup>+</sup>) from PBMC were analysed by flow cytometry. (D) Graphical representation of the TSAd expression levels in human CD3<sup>-</sup>CD56<sup>+</sup> cells +/- SEM (\*p < 0.05). Each dot represents an individual donor.

Finally, an MCMV strain that lacks the m157 protein ( $\Delta$ m157 MCMV) and thus bypasses the stringent Ly49H NK cell response<sup>27</sup> has enabled the discovery of CD8<sup>+</sup> T cell and NK cell cross talk during viral infection<sup>28</sup>. While CD8<sup>+</sup> T cells have only a minor role in the control of wild type MCMV, they have a critical function in the clearance of m157-deficient virus<sup>28</sup>. This detailed understanding of MCMV and its interaction with NK and CD8<sup>+</sup> T cells together with availability of *Sh2d2a*<sup>-/-</sup> mice provide ideal tools for investigating the function of TSAd in the context of infection.

Here, we report the use of various virus infection models, including  $\Delta$ m157 MCMV, to assess the function of TSAd during a primary viral infection. Absence of an altered anti-virus response in wild type MCMV infected *Sh2d2a*<sup>-/-</sup> mice, and impaired viral clearance in  $\Delta$ m157 MCMV infected *Sh2d2a*<sup>-/-</sup> mice indicates that TSAd does not modulate NK cell function through the Ly49H activating pathway and suggests that TSAd is implicated in T cell mediated elimination of virus infected cells.


## Results and discussion

**TSAd is expressed in NK cells.** To confirm expression of TSAd in activated NK cells from C57BL/6 *Sh2d2a*<sup>+/+</sup> mice, splenic NK cells were cultured in the presence IL-2 for six to eight days. Western blot analysis demonstrated expression of TSAd in IL-2 activated NK cells, and increased expression following incubation in a cocktail of PMA plus ionomycin. Similarly, the human NK cell line NKL (cultured in IL-2) demonstrated increased expression of TSAd following induction with PMA/ionomycin as analysed by western blot (Figure 1A–B). The mouse NK cells displayed a rapid increase in TSAd expression, evident as early as 10 minutes following PMA/ionomycin stimulation indicating that the expression of TSAd is regulated also at the translational level as reported earlier<sup>29</sup>. In contrast, the human NKL cell line displayed a slower response, with TSAd

expression peaking eight hours after stimulation (Figure 1A–B). The amount of TSAd in primary human NK cells from blood as analysed by flow cytometry was not affected by addition of IL-2. However, a significant increase in amount of TSAd was observed upon treatment with IL-2/PHA or PMA/Ionomycin (Figure 1C–D).

**TSAd deficient mice display reduced clearance of  $\Delta$ m157 MCMV infection in the spleen.** In order to determine if TSAd influences host resistance to MCMV infection, *Sh2d2a*<sup>-/-</sup> mice and their *Sh2d2a*<sup>+/+</sup> littermates were infected with both wild type (Smith strain) MCMV and the  $\Delta$ m157 MCMV strain, lacking the m157 gene, and viral titers in spleen and liver were determined. Infection with MCMV at day 4 did not show a difference between *Sh2d2a*<sup>-/-</sup> and wild type mice neither in the spleen nor the liver (Figure 2A–B). In contrast, 5 days post infection with  $\Delta$ m157 MCMV, the *Sh2d2a*<sup>-/-</sup> mice displayed higher viral titers in the spleen but not the liver, than the *Sh2d2a*<sup>+/+</sup> mice (Figure 2C–D). NK cells are critical in clearing MCMV via recognition of the viral MHC homologue m157 by Ly49H<sup>28,30</sup>. The observation that wild type MCMV was cleared equally well in TSAd deficient mice and wild type mice (Figure 2A–B), indicates that TSAd is not critical for clearance of the virus by Ly49H-dependent NK cells.

MCMV infection of mice lacking Ly49H (B6. *Ly49h*-deficient mice) leads to high splenic viral titer, disorganization of the spleen architecture and dramatic attrition of lymphocytes during the first three days after infection<sup>30</sup>. In absence of Ly49H signaling, however, CD8<sup>+</sup> T cells have been shown to be critical for the control of infection<sup>28,30</sup>. This was demonstrated in a model whereby C57BL/6 mice are infected with  $\Delta$ m157 MCMV<sup>28,30</sup>. Already by day 4 post-infection, CD8<sup>+</sup> T cells express activation markers and, by day 7, there is robust proliferation and cytokine secretion of antigen-specific CD8<sup>+</sup> T cells<sup>28,30</sup>.



**Figure 2** | *Sh2d2a* genotype influences host control of MCMV  $\Delta m157$  but not MCMV virus replication. *Sh2d2a*<sup>+/+</sup> and *Sh2d2a*<sup>-/-</sup> littermates were infected with 7000 PFU of MCMV (Smith strain) or  $2 \times 10^6$  PFU of MCMV  $\Delta m157$  virus via the intravenous route. (A–B) At day 4 p.i. mice were sacrificed and the MCMV viral titers from A) spleens and B) livers were determined by standard plaque assays using BALB/c mouse embryonic fibroblasts. (C–D) After MCMV  $\Delta m157$  infection, viral titers were determined 5 days post-infection in the spleen (C) and liver (D) by standard plaque assays using BALB/c mouse embryonic fibroblasts. Each dot represents an individual mouse and results are expressed as mean  $\pm$  SEM. (\*\* $p < 0.005$ ). One out of two representative experiments is shown.


TSAd is highly expressed in activated T cells. Thus the reduced clearance of *Am157* MCMV in the spleens of *Sh2d2a*<sup>-/-</sup> mice could be caused by deficiency in CD8<sup>+</sup> T cell activation or function. However, an early NK cell response modulates CD8<sup>+</sup> T cell function during *Am157* MCMV infection<sup>28</sup>. Deficient NK cell function could also explain the reduced viral clearance in the spleen. Thus, the higher *Am157* MCMV titers seen in *Sh2d2a*<sup>-/-</sup> mice could be due to defective early NK-CD8<sup>+</sup> T cell responses or crosstalk. This dysfunction may be masked in wild type MCMV infection by the potent Ly49H-mediated effect resulting in normal resistance to the virus<sup>28</sup>.

In order to assess the relative importance of T cells versus NK cells in the reduced *Am157* MCMV clearance in *Sh2d2a*<sup>-/-</sup> mice, we assessed the absolute numbers and proportions of cell types in the spleen before and after MCMV or *Am157* MCMV infection in *Sh2d2a*<sup>-/-</sup> mice and their wild type littermates (Figure 3). To capture the contribution of both cell types, mice were examined on day 5 post-infection. A minor but significant decrease in the percentage of CD8<sup>+</sup> T cells was observed in both non-infected as well as infected *Sh2d2a*<sup>-/-</sup> mice compared to their wild type littermates (Figure 3A). Moreover, no significant changes were observed between *Sh2d2a*<sup>-/-</sup> and *Sh2d2a*<sup>+/+</sup> mice in absolute T cell numbers (Figure 3B). Thus the relative decrease in the percentage of CD8<sup>+</sup> T cells is likely due to an influx of another cell type, as there is no difference in the total numbers of CD8<sup>+</sup> T cells present in the spleens of *Sh2d2a*<sup>+/+</sup> and *Sh2d2a*<sup>-/-</sup> mice. Indeed the numbers of CD4<sup>+</sup> T cells and B cells are

both nominally increased in *Sh2d2a*<sup>-/-</sup> mice compared to controls although the difference does not reach significance (Fig. 3B). B cells are required for the initial type I IFN response to MCMV<sup>31</sup>. However, as TSAd is not expressed in B-cells, we find it less likely that these cells are responsible for the reduced clearance of *Am157* MCMV in *Sh2d2a*<sup>-/-</sup> mice. Finally, NK cell numbers show no major differences between the two groups (Figure 3B), suggesting a possible functional defect in NK or CD8<sup>+</sup> T cells.

**NK cells from TSAd deficient mice display normal distribution of maturation and activation markers in vivo and in vitro.** NK cell maturation was analyzed by the expression of CD27 and CD11b during infection with *Am157* MCMV in spleen lymphocytes. The order of maturity from least to most mature is CD11b<sup>low</sup>CD27<sup>low</sup>, CD11b<sup>low</sup>CD27<sup>high</sup>, CD11b<sup>high</sup>CD27<sup>high</sup> and finally CD11b<sup>high</sup>CD27<sup>low</sup><sup>32</sup>. As the cell matures along these stages, the NK cell effector functions change, and the levels of CD11b and CD27 expression may thus correlate with how capable the population of NK cells are at clearing MCMV.

In order to assess whether there was a difference in NK maturation between *Sh2d2a*<sup>-/-</sup> mice and wild type controls, levels of CD11b and CD27 on the surface of NK cells were analyzed 5 days post infection with *Am157* MCMV. No differences in any of the stages were observed between *Sh2d2a*<sup>-/-</sup> mice and their wild type littermates (Figure 4A–C). The level of the activation marker KLRG1 on NK cells



**Figure 3 | Cell populations of the splenic compartment in *Sh2d2a*<sup>+/+</sup> and *Sh2d2a*<sup>-/-</sup> mice.** Mice were infected with 8000 PFU of WT MCMV or 2 \* 10<sup>6</sup> PFU of  $\Delta$ 157 MCMV. Splenocytes were harvested from uninfected mice or at day 5 post-infection and analyzed for proportions (A) or absolute numbers (B) of spleen cell populations +/- SEM (\**p* < 0.05; \*\**p* < 0.005). Each dot represents an individual mouse. One out of two representative experiments is shown.

also showed no difference prior to and after 5 days of *Am157* MCMV infection (Figure 4D). Thus, the maturity and activation profile of NK cells are similar in the two groups of mice.

To investigate whether lack of TSAAd had an effect on the ability of NK cells to be activated and produce IFN $\gamma$ , total splenocytes were stimulated *in vitro* with antibodies against the activating NK cell receptors Ly49D, Ly49H, NKp46 or NK1.1. Stimulation with IL12 + IL18 or PMA plus ionomycin served as positive controls. IFN $\gamma$  expression in NK cells was subsequently measured by flow cytometry. No differences in IFN $\gamma$  expression were observed between NK cells from *Sh2d2a*<sup>-/-</sup> and wild type donors (Figure 4E). Also, the levels of IFN $\gamma$  in CD8+ T cells upon IL12 + IL18 or PMA/ionomycin stimulation were not significantly different between *Sh2d2a*<sup>-/-</sup> and wild type mice (data not shown).

**Reduced proliferation of TSAAd deficient NK and CD8+ T cells during infection with  $\Delta$ 157 MCMV.** Although *Sh2d2a*<sup>-/-</sup> mice are capable of clearing MCMV infection, there may be a defect in the ability of NK cells to proliferate in the absence of TSAAd. TSAAd's effect on the proliferation of T cells has been disputed. Some studies have found that absence of TSAAd reduces T cell proliferation<sup>2</sup>, while others have not<sup>4,33</sup>. In order to investigate TSAAd's role in NK cell proliferation, BrdU incorporation was measured in splenocytes from *Sh2d2a*<sup>-/-</sup> mice and their wild type littermates 5 days after *Am157* MCMV infection. Five days after infection we observed a significant decrease of 50% on average in the total number of NK cells in infected mice, as it has been previously reported<sup>28,30</sup> (Figure 4F). The number of NK cells during infection was not significantly different between *Sh2d2a*<sup>-/-</sup> mice and controls (Figure 4F). In contrast, while the total number of BrdU+ NK cells in spleen remained similar at day 5 post infection *Am157* MCMV (Figure 4G), a lower proportion of spleen NK cells were BrdU+ in TSAAd deficient mice (Figure 4H). This suggested reduced NK cell proliferation in the absence of TSAAd in *Am157* MCMV infection. The reduced BrdU incorporation, in the presence of similar NK cell numbers, indirectly implicates a higher turnover of NK cells in the wild type animals. No difference in cell number but a difference in the proportion of BrdU+ CD8+ T lymphocytes was also observed in *Sh2d2a*<sup>-/-</sup> mice during *Am157* MCMV infection (Figure 4I–K). The decay in NK cells 5 days post-infection was previously described during infection with *Am157* MCMV<sup>28,30</sup>. Here we show that at this early time-point after infection CD8+ T cells display normal levels both in wild-type and *Sh2d2a*<sup>-/-</sup> mice (Figure 4J), possibly because CD8+ T cells have already recovered. No significant differences were observed


in the numbers or frequency of BrdU uptake in CD4+ T cells (data not shown).

To examine whether the proliferation defect in *Sh2d2a*<sup>-/-</sup> NK cells was at the level of receptor repertoire and recognition, the fractions of NK cell populations expressing the activating or inhibitory NK cell receptors KLRG1, Ly49A, Ly49C, Ly49D, Ly49H and NKG2A on the surface were measured by flow cytometry. No significant differences between *Sh2d2a*<sup>-/-</sup> mice and their wild type littermates were observed for these receptors (Figure 4L). The decreased BrdU+ incorporation in NK cell and CD8+ T cells from *Sh2d2a*<sup>-/-</sup> mice could be the result of an increased cell turnover or an increased migration towards peripheral target organs of MCMV infection. NK cells from the spleen migrate via a chemokine-cytokine-chemokine pathway towards the liver. The liver is an important organ of MCMV replication, and at later time-points during infection, NK cells and CD8+ T cells have been shown to contribute to the control of virus titer in this organ.

**Normal susceptibility to herpes simplex virus 1, coxsackievirus B3 and influenza virus infections in TSAAd deficient mice.** To further explore the role of TSAAd in anti-viral immune responses, three additional viral infection models were explored: herpes simplex virus 1, coxsackievirus B3 and influenza virus. Quite different in their genomes and inducing qualitatively different host responses; all three viruses have a strong public health impact and their clearance is mostly mediated by T cells and NK cells. No differences between *Sh2d2a*<sup>-/-</sup> mice and their wild type littermates were observed in the resistance towards these three viruses (Suppl. Figure 1).

**Conclusion.** There is currently no evidence that TSAAd directly modulates NK cell efficacy in clearing viral infections. Indeed, this study revealed no difference in resistance to MCMV, herpes simplex, coxsackie virus or influenza virus of *Sh2d2a*<sup>-/-</sup> mice. Interestingly, infection with the *Am157* MCMV variant yielded higher viral titers in the spleens but not livers of *Sh2d2a*<sup>-/-</sup> mice. Our results also suggest a reduced proliferative response in spleen NK cells in TSAAd deficient mice. Taken together with the observed normal clearance of wild type MCMV, our data indicate that TSAAd does modulate NK cell function, but is not necessary for activation of NK cells through the Ly49H activating receptor.

The reason why *Sh2d2a*<sup>-/-</sup> mice did not show a defect in viral clearance in the liver upon *Am157* MCMV infection could be the tissue specific antiviral role of NK cells. For example NK cells from salivary glands, an important reservoir of persistent MCMV infec-



**Figure 4 | In vivo and in vitro Immunophenotyping of NK cells in *Sh2d2a*<sup>+/+</sup> and *Sh2d2a*<sup>-/-</sup> mice.** Total leukocytes were isolated from mice uninfected or infected with  $2 \times 10^6$  PFU of MCMV  $\Delta$ m157 for 5 days. *Ex vivo* splenic NK cell subsets were gated according to surface expression of maturation markers CD11b and CD27 (A–C) or expression of KLRG1 (D). Explanted lymphocytes from uninfected *Sh2d2a*<sup>+/+</sup> and *Sh2d2a*<sup>-/-</sup> mice served to determine *in vitro* NK cell expression levels of IFN $\alpha$  upon stimulation with plate bound antibodies ( $x$ -axis), PMA/Ionomycin and IL12/IL18 (E). Total number of CD3<sup>-</sup>DX5<sup>+</sup> splenocytes before and after infection with  $\Delta$ m157 for 5 days (F). NK proliferation was monitored by BrdU incorporation and staining with anti-BrdU in CD3<sup>-</sup>DX5<sup>+</sup> splenocytes *ex vivo*. Total number (G) and frequency (H) of BrdU positive cells was determined by flow cytometry. Total number of CD3<sup>-</sup>CD8<sup>+</sup> splenocytes before and after infection with  $\Delta$ m157 for 5 days (I). CD8<sup>+</sup> T cell proliferation was monitored by BrdU incorporation and staining with anti-BrdU in CD3<sup>-</sup>DX5<sup>+</sup> splenocytes *ex vivo*. Total number (J) and frequency (K) of BrdU positive cells was determined by flow cytometry. Explanted lymphocytes from uninfected *Sh2d2a*<sup>+/+</sup> and *Sh2d2a*<sup>-/-</sup> mice served to determine *in vitro* levels of surface activating and inhibitory NK cell receptors (L). Results are expressed as mean  $\pm$  SEM. \* $<0.05$ , \*\* $<0.05$ .

tion, are hyporesponsive<sup>34</sup>. Equally, even in MCMV-resistant mice at relatively early times post-infection, which is those that were chosen for this study, control of virus replication by NK cells occurs principally in the spleen<sup>35</sup>.

In response to MCMV infection, NK cells secrete cytokines, display cytotoxic activity and proliferate. In the liver MCMV induces an innate cytokine/chemokine network involving the recruitment of MIP-1 $\alpha$  producing macrophages. MIP-1 $\alpha$  is a chemoattractant also for INF $\gamma$  producing NK cells, which are able to control virus load in the liver starting at around day 6<sup>36,37</sup>. It is therefore likely that any defect in viral clearance in the liver would be observed only after day 5, which was examined in this study.

Important biological functions can often be difficult to reveal in knock-out models because of functional redundancies. This may also be the case of TSAd, thus other signaling proteins and alternate pathways may have compensated for the lack of TSAd in these experiments. Although more advanced models could help reveal the mechanistic role of TSAd in NK cells in virus infections, our data indicate that TSAd is involved in modulating viral clearance, and provide a direction for further dissecting the observed susceptibility in the context of  $\Delta$ m157 MCMV infection.

## Methods

**Ethical Statement.** Human PBMC were collected with informed consent from healthy blood donors. Collection and analysis of samples were approved by and

performed in accordance with the guidelines of the regional ethical committee. The animal protocols and experiments were approved by and performed in accordance with the guidelines of the National Animal Research Authority (Oslo, Norway), the Canadian Council on Animal Care (CCAC) and the McGill University Animal Resources Center.

**Mice.** The *Sh2d2a*<sup>-/-</sup> C57BL/6 mice have been previously described<sup>26</sup>. Briefly *Sh2d2a* knockout mice were backcrossed on a C57BL/6–129 background (N8, kindly provided by Professor Jeffrey Bluestone<sup>2</sup>) to C57BL/6 (purchased from the Norwegian Institute of Public Health) for more than 10 generations and then to homozygosity for the disrupted *Sh2d2a* allele.

**In vitro TSAd expression.** Mouse NK cell cultures were generated by culturing total splenocytes in recombinant human IL-2 (1000 U/mL) for 6 to 8 days. The proportion of NK cells was then verified by flow cytometry with more than 90% purity (CD49b (DX5)<sup>+</sup>, CD3<sup>-</sup>).  $2 \times 10^6$  cells were left unstimulated, or stimulated for indicated times with PMA (100 ng/ml) and ionomycin (1  $\mu$ g/ml) then lysed in presence of protease inhibitors, and phosphatase inhibitors before being subjected to western blotting.

Human NKL cells were grown in complete RPMI-1640 media (10% fetal bovine serum, 1 mM sodium pyruvate, 10 mM HEPES, 1% Pen/strep; Wisent) with the addition of 200 U/ml of IL-2.  $2 \times 10^6$  cells ( $1 \times 10^6$  cells/ml) human PBMC and NKL cells were stimulated with 100 ng/ml of PMA and 500 ng/ml of ionomycin for different time intervals depicted in the figure legends. For western blot analysis, cells were lysed using 0.1% LDS-1% Triton X-100 solution containing 50 mM HEPES, 0.05 M lithium chloride, 0.5 mM PMSF, 2.5 mM EDTA (pH 8.0), 1 mM sodium vanadate and 1% Triton. The cells were lysed with LDS for 15 min and then with Triton for 30 min. After lysis, the cells were sonicated, boiled with SDS loading buffer before proteins were separated by SDS-PAGE and transferred to PVDF membrane (Bio Rad) using a Hoefer Semi-Phor Semi-Dry transfer unit (Amersham Biosciences).



The membranes were blocked with Tris-buffered saline (pH 7.4) containing 0.1% Tween 20 (Sigma Aldrich) and 5% skimmed milk, and subsequently incubated with Anti-TSAd (Origene), Anti-GADPH (Chemicon) or Goat anti Mouse (Jackson) in blocking buffer containing 1% skimmed milk. Signals were detected using ECF substrate (GE Healthcare, Pittsburgh, PA, USA) and Storm 860 (GE). Densitometry analysis was performed on the Western blot data using ImageJ.

**MCMV viruses, Infections and Viral Loads.** Salivary gland MCMV was prepared by passaging the virus (Smith strain ATCC VR-1399) twice in 3-week old BALB/c mice. The virus was prepared from a homogenate of salivary glands 21 days p.i. Mice aged between 7 and 9 weeks were infected intravenously with 8,000 PFUs of MCMV for 3 or 5 days. The tissue culture-grown viruses<sup>38</sup> *Am157* MCMV, which lacks the m157 open reading frame (ORF), have been previously described<sup>39</sup>. Mice were infected with  $2 \times 10^6$  PFU of *Am157* MCMV for 5 days. Viral titers of the stock virus or mouse organs (spleen and liver) were evaluated *in vitro* by standard plaque assays on a confluent BALB/c mouse embryonal fibroblast monolayer, as previously described<sup>40</sup>.

**Flow cytometry.** For analysis of PBMC cells by flow cytometry after stimulation, the cells were stained for surface markers (CD3-PE (Immunotools) and CD56-PE-Cy7 (eBioscience)) for human PBMC in PBS containing 2% FCS and 0.1% NaN<sub>3</sub> at 4°C. Cells were then fixed in 2% paraformaldehyde and permeabilized in 0.1% saponin before intracellular staining with anti-TSAd-Dyelight 488 (3C7) from Origene. For analysis of splenic leucocytes from mice, spleens from MCMV-infected and uninfected mice were removed aseptically and gently mashed through a 70 µm nylon mesh (BD Bioscience). Red blood cells were lysed with Ack's Lysis Buffer and the remaining cells were resuspended in the FACS staining buffer. All cells were incubated with 2.4G2 antibodies to block Fc receptors prior to staining, then stained with extracellular Ab, fixed, permeabilized and stained for intracellular antigens using BD cytofix/cytoperm kit according to the manufacturer's protocol. To detect incorporated BrdU on NK and T cells, mice were injected i.p. with BrdU (sigma) 3 hours before sacrificing and collecting the spleen. The cells were first blocked with 2.4G2 antibody and stained for surface antigens and then fixed, permeabilized, treated with DNase I, and stained with FITC-conjugated anti-BrdU antibody (clone 3D4; BD Biosciences), according to the manufacturer's protocol. All the antibodies used in this work were purchased from e-Bioscience, Biologend or R&D systems, CD3 (2C11), CD4 (GK1.5), CD8 (53-6.7), B220 (RA3-6B2), CD11b (M1/70), CD27 (LG.3A10), DX5 (CD49b), NKp46 (CD335), Ly49A/D (12A8), Ly49C/E/H/I (14B11), Ly49D (4E5), NKG2A/C/E (20d5), KLRG1 (2F1), Ly49H (3D10), IFNg (XMG1.2).

**In vitro Cell Stimulations.** Splenocytes were extracted and prepared as described above. Prior to 2.4G2 blocking and staining, cells were aliquoted into a 96-well 2HB Immulon plate that had been coated with purified antibody against NK1.1, NKp46, Ly49H, Ly49D, a cocktail of all mentioned antibodies or PMA/Ionomycin or IL12 + IL18 as a positive control. Cells were stimulated in complete RPMI-1640 media with protein transport inhibitors (GolgiStop or Golgiplug; BD). Cells were then incubated for 5 h at 37°C, and then extracellular and intracellular staining was performed as described in the FACS section.

**Herpes Simplex Virus 1 Infection and Phenotyping.** Details of the HSV-1 infection procedure have been previously described<sup>41</sup>. Briefly, mice 7 weeks of age or older were, when indicated, infected intraperitoneally (i.p.) or intranasally (i.n.) with  $1.10^4$  or  $5.10^3$  PFU of HSV-1 strain 17, respectively. In the i.n. inoculation model, mice were anesthetized prior to infection with 5 mg/ml ketamine and 15 mg/ml xylazine. Infected mice were monitored 1–2 times daily over a 2-week period for survival and weight loss. Mice that succumbed to infection within 14 days post-infection (p.i.) were considered susceptible to HSV-1.

**Coxsackievirus B3 Infection and Phenotyping, weight loss, PA and Myocarditis Score.** Mice were inoculated intraperitoneally with 10 PFU of CVB3 H3 (generously provided as a plasmid by the laboratory of Dr. Kirk Knowlton<sup>42</sup>) per gram of body weight at 7–8 weeks of age. Animals were weighed daily and at day 8 post-infection, hearts were removed aseptically and sagittally bisected. Heart viral titers were quantified as previously described<sup>43</sup>. Heart sections were fixed in 10% formalin and embedded in paraffin. Samples were sent to the Histology core at the University of Montreal where sections were prepared. Contiguous heart sections were fixed on slides and stained with hematoxylin and eosin (H&E) for evaluation of myocarditis as previously described<sup>44</sup>.

**Influenza Infection and weight loss.** Mice were anesthetized with a ketamine/xylazine mixture and infected via intra-nasal inoculation. Each mouse received a weight-adjusted dose of 68 PFU/g of the mouse adapted influenza strain A/HK/1/68-MA20. This strain was derived from a H3N2 clinical isolate of seasonal human influenza from the 1968 Hong Kong pandemic, as previously reported<sup>45</sup>. The bodyweight of animals was monitored daily for two weeks following infection. Mice presenting respiratory distress were humanely sacrificed.

- Spurkland, A. *et al.* Molecular cloning of a T cell-specific adapter protein (TSAd) containing an Src homology (SH) 2 domain and putative SH3 and phosphotyrosine binding sites. *J Biol Chem* **273**, 4539–4546 (1998).
- Rajagopal, K. *et al.* RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation. *J Exp Med* **190**, 1657–1668 (1999).

- Drappa, J. *et al.* Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice. *J Exp Med* **198**, 809–821, doi:10.1084/jem.20021358 (2003).
- Berge, T. *et al.* SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice. *PLoS One* **7**, e48239, doi:10.1371/journal.pone.0048239 (2012).
- Granum, S. *et al.* Modulation of Lck function through multisite docking to T cell-specific adapter protein. *J Biol Chem* **283**, 21909–21919, doi:10.1074/jbc.M800871200 (2008).
- Berge, T. *et al.* T cell specific adapter protein (TSAd) interacts with Tec kinase ITK to promote CXCL12 induced migration of human and murine T cells. *PLoS One* **5**, e9761, doi:10.1371/journal.pone.0009761 (2010).
- Sundvold-Gjerstad, V. *et al.* The C terminus of T cell-specific adapter protein (TSAd) is necessary for TSAd-mediated inhibition of Lck activity. *Eur J Immunol* **35**, 1612–1620, doi:10.1002/eji.200425638 (2005).
- Sundvold, V. *et al.* T cell-specific adapter protein inhibits T cell activation by modulating Lck activity. *J Immunol* **165**, 2927–2931 (2000).
- Nejad, S. *et al.* cDNA cloning of a rat orthologue of SH2D2A encoding T-cell-specific adaptor protein (TSAd): expression in T and NK cells. *Immunogenetics* **56**, 338–342, doi:10.1007/s00251-004-0695-9 (2004).
- Choi, Y. B., Kim, C. K. & Yun, Y. Lad, an adapter protein interacting with the SH2 domain of p56lck, is required for T cell activation. *J Immunol* **163**, 5242–5249 (1999).
- Sun, W. *et al.* MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. *J Biol Chem* **276**, 5093–5100, doi:10.1074/jbc.M003719200 (2001).
- Khurana, D., Arneson, L. N., Schoon, R. A., Dick, C. J. & Leibson, P. J. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. *J Immunol* **178**, 3575–3582 (2007).
- Felices, M. & Berg, L. J. The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival. *J Immunol* **180**, 3007–3018 (2008).
- Nishio, K., Miura, K., Ohira, T., Heike, Y. & Saijo, N. Genistein, a tyrosine kinase inhibitor, decreased the affinity of p56lck to beta-chain of interleukin-2 receptor in human natural killer (NK)-rich cells and decreased NK-mediated cytotoxicity. *Proc Soc Exp Biol Med* **207**, 227–233 (1994).
- Vyas, Y. M., Maniar, H. & Dupont, B. Cutting edge: differential segregation of the SRC homology 2-containing protein tyrosine phosphatase-1 within the early NK cell immune synapse distinguishes noncytolytic from cytolytic interactions. *J Immunol* **168**, 3150–3154 (2002).
- Inngjerdigen, M., Torgersen, K. M. & Maghazachi, A. A. Lck is required for stromal cell-derived factor 1 alpha (CXCL12)-induced lymphoid cell chemotaxis. *Blood* **99**, 4318–4325 (2002).
- Yuan, J. *et al.* CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. *Circ Res* **104**, 628–638, doi:10.1161/circresaha.108.192179 (2009).
- Nogusa, S., Ritz, B. W., Kassim, S. H., Jennings, S. R. & Gardner, E. M. Characterization of age-related changes in natural killer cells during primary influenza infection in mice. *Mech Ageing Dev* **129**, 223–230, doi:10.1016/j.mad.2008.01.003 (2008).
- Chew, T., Taylor, K. E. & Mossman, K. L. Innate and adaptive immune responses to herpes simplex virus. *Viruses* **1**, 979–1002, doi:10.3390/v1030979 (2009).
- Lee, S. H. *et al.* Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. *Nat Genet* **28**, 42–45, doi:10.1038/88247 (2001).
- Brown, M. G. *et al.* Vital involvement of a natural killer cell activation receptor in resistance to viral infection. *Science* **292**, 934–937, doi:10.1126/science.1060042 (2001).
- Moussa, P., Marton, J., Vidal, S. M. & Fodil-Cornu, N. Genetic dissection of NK cell responses. *Front Immunol* **3**, 425, doi:10.3389/fimmu.2012.00425 (2012).
- Jonjic, S., Mutter, W., Weiland, F., Reddehase, M. J. & Koszinowski, U. H. Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. *J Exp Med* **169**, 1199–1212 (1989).
- Walton, S. M. *et al.* Absence of cross-presenting cells in the salivary gland and viral immune evasion confine cytomegalovirus immune control to effector CD4 T cells. *PLoS Pathog* **7**, e1002214, doi:10.1371/journal.ppat.1002214 (2011).
- Stacey, M. A. *et al.* Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV. *Cell Host Microbe* **15**, 471–483, doi:10.1016/j.chom.2014.03.003 (2014).
- Tyznik, A. J., Verma, S., Wang, Q., Kronenberg, M. & Benedict, C. A. Distinct requirements for activation of NKT and NK cells during viral infection. *J Immunol* **192**, 3676–3685, doi:10.4049/jimmunol.1300837 (2014).
- Voigt, V. *et al.* Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. *Proc Natl Acad Sci USA* **100**, 13483–13488, doi:10.1073/pnas.2233572100 (2003).
- Mitrovic, M. *et al.* The NK cell response to mouse cytomegalovirus infection affects the level and kinetics of the early CD8(+) T-cell response. *J Virol* **86**, 2165–2175, doi:10.1128/JVI.06042-11 (2012).
- Kolltveit, K. M. *et al.* Expression of SH2D2A in T-cells is regulated both at the transcriptional and translational level. *Mol Immunol* **45**, 2380–2390, doi:10.1016/j.molimm.2007.11.005 (2008).



30. Fodil-Cornu, N. *et al.* Ly49h-deficient C57BL/6 mice: a new mouse cytomegalovirus-susceptible model remains resistant to unrelated pathogens controlled by the NK gene complex. *J Immunol* **181**, 6394–6405 (2008).
31. Schneider, K. *et al.* Lymphotoxin-mediated crosstalk between B cells and splenic stroma promotes the initial type I interferon response to cytomegalovirus. *Cell Host Microbe* **3**, 67–76, doi:10.1016/j.chom.2007.12.008 (2008).
32. Chiossone, L. *et al.* Maturation of mouse NK cells is a 4-stage developmental program. *Blood* **113**, 5488–5496, doi:10.1182/blood-2008-10-187179 (2009).
33. Perchonock, C. E., Pajeroski, A. G., Nguyen, C., Shapiro, M. J. & Shapiro, V. S. The related adaptors, adaptor in lymphocytes of unknown function X and Rlk/Irk-binding protein, have nonredundant functions in lymphocytes. *J Immunol* **179**, 1768–1775 (2007).
34. Tessmer, M. S., Reilly, E. C. & Brossay, L. Salivary gland NK cells are phenotypically and functionally unique. *PLoS Pathog* **7**, e1001254, doi:10.1371/journal.ppat.1001254 (2011).
35. Scalzo, A. A., Fitzgerald, N. A., Simmons, A., La Vista, A. B. & Shellam, G. R. Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. *J Exp Med* **171**, 1469–1483 (1990).
36. Salazar-Mather, T. P., Hamilton, T. A. & Biron, C. A. A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense. *J Clin Invest* **105**, 985–993, doi:10.1172/jci9232 (2000).
37. Salazar-Mather, T. P. & Hokeness, K. L. Cytokine and chemokine networks: pathways to antiviral defense. *Curr Top Microbiol Immunol* **303**, 29–46 (2006).
38. Brune, W., Hengel, H. & Koszinowski, U. H. A mouse model for cytomegalovirus infection. *Curr Protoc Immunol* **Chapter 19**, Unit 19 17, doi:10.1002/0471142735.im1907s43 (2001).
39. Bubic, I. *et al.* Gain of virulence caused by loss of a gene in murine cytomegalovirus. *J Virol* **78**, 7536–7544, doi:10.1128/JVI.78.14.7536-7544.2004 (2004).
40. Depatie, C. *et al.* Assessment of Cmv1 candidates by genetic mapping and in vivo antibody depletion of NK cell subsets. *Int Immunol* **11**, 1541–1551 (1999).
41. Caignard, G. *et al.* Genome-wide mouse mutagenesis reveals CD45-mediated T cell function as critical in protective immunity to HSV-1. *PLoS Pathog* **9**, e1003637, doi:10.1371/journal.ppat.1003637 (2013).
42. Knowlton, K. U., Jeon, E. S., Berkley, N., Wessely, R. & Huber, S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. *J Virol* **70**, 7811–7818 (1996).
43. Wiltshire, S. A., Leiva-Torres, G. A. & Vidal, S. M. Quantitative trait locus analysis, pathway analysis, and consomic mapping show genetic variants of Tnni3k, Fpqt, or H28 control susceptibility to viral myocarditis. *J Immunol* **186**, 6398–6405, doi:10.4049/jimmunol.1100159 (2011).
44. Aly, M., Wiltshire, S., Chahrour, G., Osti, J. C. & Vidal, S. M. Complex genetic control of host susceptibility to coxsackievirus B3-induced myocarditis. *Genes Immun* **8**, 193–204, doi:10.1038/sj.gene.6364374 (2007).
45. Brown, E. G., Liu, H., Kit, L. C., Baird, S. & Nesrallah, M. Pattern of mutation in the genome of influenza A virus on adaptation to increased virulence in the mouse lung: identification of functional themes. *Proc Natl Acad Sci U S A* **98**, 6883–6888, doi:10.1073/pnas.111165798 (2001).

## Acknowledgments

This work was supported by grants from the Norwegian Research Council (grant no 196386), Unifor, Legatet til Henrik Homans Minde, Anders Jahres fond til vitenskapens fremme, the University of Oslo, and Canadian Institutes of Health Research (MOP7781).

## Author contributions

P.M. and G.A. designed, performed experiments, analyzed data and wrote the main manuscript text. N.F. designed and performed experiments and analyzed data, R.G., P.S., S.W., G.B. and G.C. performed experiments. M.M. analyzed data, E.D., A.S. and S.V. designed experiments, analyzed data and contributed to the writing of the paper. All authors reviewed and approved the final version of the manuscript.

## Additional information

**Supplementary information** accompanies this paper at <http://www.nature.com/scientificreports>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Moussa, P. *et al.* Reduced MCMV  $\Delta$ m157 viral clearance in the absence of TSA. *Sci. Rep.* **5**, 9219; DOI:10.1038/srep09219 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>